Irvine, CA—A combination of TheraPrimE palm tocotrienols and AstaZine astaxanthin, both from BGG World, has been shown in a new clinical trial to improve cognitive health in subjects with age-related memory decline.
The randomized, double-blind, placebo-controlled study was performed on 36 subjects over 12 weeks. The test group used 50mg TheraPrimE and 9mg AstaZine. Cognitive tests found a statistically significant improvement in composite memory—the primary outcome—in the test group as opposed to the placebo group. Subjectively, people in the test group felt that their memories had improved more than those in the placebo group, noting fewer times when they had forgotten things in recent weeks than the placebo group had.
The study noted no safety issues.
Related: Study: AstaZine May Improve Mental Health
Benefits of Omega-3 on Alzheimer’s Patients Reliant on Dose
CBD May Improve Blood Flow to Hippocampus, Study Suggests
Looking to the future, the researchers hope to see studies that determine how AstaZine and TheraPrimE function, and whether the benefits are sustainable even after people stop taking the combination.
Lead author Takahiro Sekikawa, Ph.D., commented in a press release: “We previously demonstrated that AstaZine Natural Astaxanthin alone was able to markedly ameliorate how well subjects can recognize, remember, and retrieve words and geometric figures. In this study we decided to add 50mg of tocotrienols to the same dosage of Astaxanthin previously tested and we were able to show a statistically significant amelioration versus the placebo group on Cognitrax in addition to improvement in all subjective symptoms measured. Previous research has established synergistic antioxidant performance of a Tocotrienol + Astaxanthin blend, and it would be of great interest to investigate in future studies if this outcome is due to an ameliorated absorption of Astaxanthin or perhaps to increased antioxidant activity due to the addition of tocotrienols.”